Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Completed · Phase 1
Conditions studied: Prostate Cancer
In brief
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer.
Key facts
- Study ID
- NCT00036933
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 9
- Starts
- 2002-03-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2013-03-25
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.